€40M in Series C for a British Biotech Treating Blindness with Gene Therapy – Labiotech.eu (blog)
|
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
Labiotech.eu (blog) NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the … |
